Conference Preview: Joint Cancer Conference 2000 III. Translational Research

Yagoda A. , Abi-Rached B. , Petrylak D. . Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol. 1995; 22: 42–60.

Fyfe G. , Fisher R.I. , Rosenberg S.A. . Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995; 13: 688–696.

Yang J.C. , Rosenberg S.A. . An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am. 1997; 3(suppl 1): S79–S84.

O'Dea M.J. , Zincke H. , Utz D.C. . The treatment of renal cell carcinoma with solitary metastasis. J Urol. 1978; 120: 540–542.

Bukowski R.M. , Novick A.C. . Clinical practice guidelines: renal cell carcinoma. Cleve Clin J Med. 1997; 64(suppl 1): S11–S44.

Motzer R.J. , Bander N.H. , Nanus D.M. . Renal-cell carcinoma. N Engl J Med. 1996; 335: 865–875.

Linehan W.M. , Shipley W. , Parkinson D. . Cancer of the kidney and ureter. In: DeVita VT Jr , Hellman S. , Rosenberg S.A. , eds. Cancer: Principles and Practice of Oncology. Philadelphia, Pa: JB Lippincott; 1993: 1023–1051.

Gleave M.E. , Elhilali M. , Fradet Y. . Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med. 1998; 338: 1265–1271.

Walther M.M. , Yang J.C. , Pass H.I. . Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol. 1997; 158: 1675–1678.

Novick A.C. . Current surgical approaches, nephron-sparing surgery, and the role of surgery in the integrated immunologic approach to renal-cell carcinoma. Semin Oncol. 1995; 22: 29–33.

Rackley R. , Novick A. , Klein E. . The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol. 1994; 152: 1399–1403.

Fallick M.L. , McDermott D.F. , LaRock D. . Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol. 1997; 158: 1691–1695.

Levy D.A. , Swanson D.A. , Slaton J.W. . Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J Urol. 1998; 159: 1168–1173.

Chang A.E. , Aruga A. , Cameron M.J. . Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol. 1997; 15: 796–807.

Figlin R.A. , Pierce W.C. , Kaboo R. . Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol. 1997; 158: 740–745.

Romero P. , Dunbar P.R. , Valmori D. . Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen- experienced tumor-specific cytolytic T lymphocytes. J Exp Med. 1998; 188: 1641–1650.

Pardoll D.M. . Cancer vaccines. Nat Med. 1998; 4: 525–531.

Roth J.A. , Cristiano R.J. . Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst. 1997; 89: 21–39.

Weidmann E. , Logan T.F. , Yasumura S. . Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes. Cancer Res. 1993; 53: 4745–4749.

Galligioni E. , Francini M. , Quaia M. . Randomized study of adjuvant immunotherapy with autologous tumor cells and BCG in renal cancer. Ann N Y Acad Sci. 1993; 690: 367–369.

Chang A.E. , Yoshizawa H. , Sakai K. . Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res. 1993; 53: 1043–1050.

Galligioni E. , Quaia M. , Merlo A. . Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer. 1996; 77: 2560–2566.

Fenton R.G. , Steis R.G. , Madara K. . A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma. J Immunother Emphasis Tumor Immunol. 1996; 19: 364–374.

Veelken H. , Mackensen A. , Lahn M. . A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer. 1997; 70: 269–277.

Simons J.W. , Jaffee E.M. , Weber C.E. . Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 1997; 57: 1537–1546.

Schwartz R.H. . Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 1992; 71: 1065–1068.

Gimmi C.D. , Freeman G.J. , Gribben J.G. . Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci U S A. 1993; 90: 6586–6590.

Chen L. , Ashe S. , Brady W.A. . Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992; 71: 1093–1102.

Boxhorn H.K. , Smith J.G. , Chang Y.J. . Adenoviral transduction of melanoma cells with B7-1: antitumor immunity and immunosuppressive factors. Cancer Immunol Immunother. 1998; 46: 283–292.

Cantrell D.A. , Smith K.A. . The interleukin-2 T-cell system: a new cell growth model. Science. 1984; 224: 1312–1316.

Smith K.A. . Rational interleukin-2 therapy. Cancer J Sci Am. 1997; 3(suppl 1): S137–S140.